314 related articles for article (PubMed ID: 31734763)
1. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
Kubala MH; DeClerck YA
Cancer Metastasis Rev; 2019 Sep; 38(3):483-492. PubMed ID: 31734763
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 in cancer research.
Li S; Wei X; He J; Tian X; Yuan S; Sun L
Biomed Pharmacother; 2018 Sep; 105():83-94. PubMed ID: 29852393
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer.
Kubala MH; Punj V; Placencio-Hickok VR; Fang H; Fernandez GE; Sposto R; DeClerck YA
Cell Rep; 2018 Nov; 25(8):2177-2191.e7. PubMed ID: 30463014
[TBL] [Abstract][Full Text] [Related]
4. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
5. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
6. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
7. The plasminogen activator inhibitor "paradox" in cancer.
Binder BR; Mihaly J
Immunol Lett; 2008 Jun; 118(2):116-24. PubMed ID: 18495253
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
Harbeck N; Krüger A; Sinz S; Kates RE; Thomssen C; Schmitt M; Jänicke F
Onkologie; 2001 Jun; 24(3):238-44. PubMed ID: 11455216
[TBL] [Abstract][Full Text] [Related]
9. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
10. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
[TBL] [Abstract][Full Text] [Related]
11. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
12. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract][Full Text] [Related]
14. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
[TBL] [Abstract][Full Text] [Related]
15. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
Stefansson S; McMahon GA; Petitclerc E; Lawrence DA
Curr Pharm Des; 2003; 9(19):1545-64. PubMed ID: 12871067
[TBL] [Abstract][Full Text] [Related]
17. Use of mouse models to study plasminogen activator inhibitor-1.
Declerck PJ; Gils A; De Taeye B
Methods Enzymol; 2011; 499():77-104. PubMed ID: 21683250
[TBL] [Abstract][Full Text] [Related]
18. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
19. Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.
Koensgen D; Stope MB; Tuerbachova I; Bruennert D; Kohlmann T; Braicu I; Sehouli J; Denkert C; Darb-Esfahani S; Stickeler E; Sofroni D; Dahl E; Mustea A
Gynecol Obstet Invest; 2018; 83(5):508-514. PubMed ID: 28738361
[TBL] [Abstract][Full Text] [Related]
20. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye.
Kwaan HC; Mazar AP; McMahon BJ
Semin Thromb Hemost; 2013 Jun; 39(4):382-91. PubMed ID: 23532574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
